ALB Inhibitors

Albumin, often abbreviated as ALB, is a crucial protein found in the blood of mammals, including humans. This globular protein is primarily synthesized by the liver and represents one of the most abundant plasma proteins in the circulatory system, making up approximately 60% of the total protein content in human blood plasma. The primary function of albumin is to maintain the osmotic pressure of blood, which is essential for proper fluid balance between the bloodstream and the tissues. Albumin plays a pivotal role in regulating the distribution of water, electrolytes, and various small molecules throughout the body, ensuring that essential nutrients and waste products are transported efficiently.

Structurally, albumin is a single-chain polypeptide consisting of 585 amino acids, organized into three domains. It possesses a high degree of solubility and stability, making it an effective carrier molecule for a wide range of substances, including fatty acids, hormones, drugs, and metabolites. This ability to bind various molecules gives albumin its multifaceted role in the body, not only as a carrier but also as a buffer for pH regulation and a contributor to antioxidant defenses. ALB inhibitors, a chemical class of compounds, are designed to selectively target and modulate the activity of albumin. Typically, these inhibitors are small molecules that interact with specific binding sites on albumin, disrupting its ability to bind to various ligands, including fatty acids and drugs. By interfering with albumin's binding capacity, ALB inhibitors can influence the distribution and transport of substances in the bloodstream, impacting various physiological processes.